Bristol Myers Squibb Looks Cheap at 4% Yield and Below-Market P/E — But the Patent Cliff Is Why the Market Disagrees

• Bristol Myers Squibb appears cheap at below-industry P/E with 4% yield, but patent cliff risk on Eliquis and Revlimid is why the market prices it at a discount
• Classic pharma value trap risk: low P/E reflects anticipated earnings decline from generic entry, not a genuine valuation opportunity without pipeline analysis
• Bull case depends on pipeline execution — Milvexian and CAR-T therapies must bridge the revenue gap or the dividend yield becomes a trap rather than an income opportunity

Bristol Myers Squibb presents a classic pharmaceutical value trap risk: trading at a below-industry-average price-to-earnings ratio with a 4% dividend yield, the stock appears attractively priced on the surface — but the one thing investors need to consider before buying is the patent cliff that threatens several of the company's most important revenue contributors. BMS's blockbuster drugs, including the anticoagulant Eliquis (co-marketed with Pfizer) and the cancer drug Revlimid, face patent expiry timelines that will allow generic entry and compress brand revenue materially. That cliff is the reason the multiple looks cheap: the market is pricing in an earnings decline that the current P/E doesn't make visible.

The value trap pattern in pharma plays out in a predictable sequence: a company with strong current earnings and a dividend commitment trades at a low multiple because sophisticated investors anticipate patent expiry revenue erosion. Retail investors see the low P/E and high yield and buy in on apparent cheapness. The patent cliff then materializes — generics enter, branded revenue declines faster than expected, the company cuts R&D or acquires expensively to replace revenue — and the dividend comes under pressure. BMS is not inevitably in this situation, but the analytical work required before buying the stock is understanding exactly how the Eliquis and Revlimid revenue decline is expected to play out and whether the pipeline has the potential to replace it.

The bull case for BMS centers on pipeline execution. The company has several advanced clinical programs — including Milvexian, a next-generation anticoagulant in Phase 3, and a portfolio of cell therapies — that could become the blockbuster successors to Eliquis and Revlimid if clinical and regulatory execution delivers. If one major pipeline drug achieves blockbuster status and begins generating significant revenue before the patent cliff impact is fully felt, the current P/E becomes an entry opportunity rather than a warning sign. The investment question is whether to pay for that optionality before clinical readouts — accepting the patent cliff risk — or wait for pipeline validation before buying, at the cost of a higher entry price.

Sources: Motley Fool (Tier 2, Tier 3) | cluster 401733